Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Company Overview

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company dedicated to discovering and developing small molecule therapies that selectively target key vulnerabilities in cancer cells. The company’s research is focused on kinase inhibitors designed to address dysregulated signaling pathways implicated in solid tumors and hematological malignancies. Prelude’s approach leverages structure-based design and translational biomarkers to advance compounds with the potential to improve outcomes for patients with limited treatment options.

Prelude’s pipeline includes several lead drug candidates in various stages of clinical and preclinical development. Among these, PRT2527 is a selective CDK8/19 inhibitor being evaluated for its ability to restore T-cell activity in the tumor microenvironment, while PRT343 targets ALK2 in rare and aggressive forms of soft-tissue sarcoma. The company is also advancing PRT1419, a potent and selective MCL-1 inhibitor, with the aim of inducing apoptotic cell death in hematologic cancers. Each program incorporates companion diagnostics and biomarker strategies to identify patient populations most likely to benefit from therapy.

Headquartered in Cambridge, Massachusetts, Prelude Therapeutics operates a central research facility in the heart of the Boston biotech corridor and collaborates with academic institutions and pharmaceutical partners worldwide. The company’s development efforts extend across the United States and into key international markets, with ongoing discussions to establish strategic alliances for late-stage clinical trials and potential commercialization. Prelude has built a network of research collaborators to enhance translational studies and accelerate timelines for regulatory submissions.

Founded in 2016 by industry veterans with extensive experience in oncology drug discovery and development, Prelude’s leadership team includes professionals who have held senior roles at leading biopharmaceutical companies. Under the guidance of its chief executive officer and chief scientific officer, the company continues to expand its pipeline through both internal discovery programs and external licensing opportunities. Prelude Therapeutics remains committed to advancing innovative therapies that address unmet medical needs in cancer care.

Key Stats

• Today's Range: $0.78 to $0.81
• 50-Day Range: $0.76 to $1.18
• 52-Week Range: $0.61 to $6.80
• Volume: 49,844 shs
• Average Volume: 290,131 shs
• Market Capitalization: $45.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

Prelude Therapeutics Stock Analysis - MarketRank™

Prelude Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 300th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Prelude Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prelude Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prelude Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prelude Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Prelude Therapeutics has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.45% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Prelude Therapeutics has recently decreased by 11.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prelude Therapeutics does not currently pay a dividend.

Dividend Growth

Prelude Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.45% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Prelude Therapeutics has recently decreased by 11.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

63.90% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRLD Stock Analysis - Frequently Asked Questions

How have PRLD shares performed this year?

Prelude Therapeutics' stock was trading at $1.2750 at the start of the year. Since then, PRLD shares have decreased by 37.3% and is now trading at $0.7990.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.05.

When did Prelude Therapeutics IPO?

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prelude Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRLD
• CIK: 1678660
• Web: www.preludetx.com
• Phone: 302-467-1280
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $5.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +463.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.17 million
• Net Margins: N/A
• Pretax Margin: -1,826.10%
• Return on Equity: -89.18%
• Return on Assets: -69.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.18
• Quick Ratio: 5.18

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 6.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.39 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 56,460,000
• Free Float: 20,382,000
• Market Cap: $45.06 million
• Optionable: Optionable
• Beta: 1.22